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Introduction
Interleukin-1b (IL-1b) is a powerful pro-inflammatory
cytokine synthesized in the inflammasome complex of
immune cells in response to injury and infection. The
excess activity of this cytokine plays a fundamental role in
the pathogenesis of the autoinflammatory disorders. An
emphasis on pediatric rheumatology is given to systemic-
onset juvenile idiopathic arthritis (SoJIA) and periodic
fever syndromes. Until the last decade, there wasnt an
efficient alternative for the treatment of autoinflammatory
syndromes refractory for convencional therapies. This
scenery was modified with the introduction of biological
agents, especially the IL-1 antagonist group (Anakinra,
Rilonacept and Canakinumab). Canakinumab, a fully
human anti-IL-1b monoclonal antibody, selectively binds
to IL-1b, and intercepts the spread of inflammation. This
medication was approved for treatment of cryopyrin-
associated periodic syndrome (CAPS) in 2009, and SoJIA
in 2013, and has shown to be an excellent tool for
controlling these disorders.
Objectives
To report the clinical and laboratorial response to the use
of Canakinumab in pediatric patients with distinct autoin-
flammatory syndromes.
Methods
We performed a retrospective chart review of patients in
use of Canakinumab in monitoring at the Rheumatology
Department of a tertiary center in Curitiba (Brazil).
Patients with arthritis (SoJIA and pediatric granuloma-
tous arthritis) received a subcutaneous dose of 4mg/kg
every 4 weeks, whereas patients with periodic fever syn-
dromes received a subcutaneous dose of 2mg/kg every
8 weeks. The clinical and laboratorial activity of these
diseases were evaluated right after the first medication
dose. The patients were monitored during the next
years in order to evaluate the long-term response to
Canakinumab.
Results
We reported 5 cases of autoinflammatory disorders: 2
cases of SoJIA, 1 neonatal-onset multisystem inflammatory
disorder (NOMID), also known as chronic infantile neuro-
logical cutaneous and articular syndrome (CINCA),
1 familial Mediterranean fever (FMF) and 1 pediatric gran-
ulomatous arthritis (Blau Syndrome). All cases showed an
excelent clinical and laboratorial response after Canakinu-
mab first dose. One SoJIA patient reported flare during
the NSAID and corticoid tapering. With the reintroduc-
tion of NSAID, the patient satisfactory responded to the
medication and the disease became inactive again. The
Blau Syndrome patient had a flare after withdrawal ther-
apy for 5 months, due to failure to receive the medication.
As soon as Canakinumab was reintroduced, the disease
was also remissioned. Neither patients showed adverse
effects.
Conclusion
Although randomized, double-blind, controlled studies
are still needed, the anti-IL-1b antibody Canakinumab
has proven to be an excellent alternative for refractory
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